ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
39,952.96
0.21%
Gold vs US Dollar
2,417.125
1.63%
Brent Oil
83.81
0.73%
Bitcoin
66,740.14
2.30%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alvontech (ALVO)

  7. Alvontech (ALVO) News

Alvontech (ALVO)

Alvontech
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALVO
DateTimeSourceHeadlineSymbolCompany
13/05/202413:00GlobeNewswire Inc.Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)NASDAQ:ALVOAlvontech
02/05/202412:15GlobeNewswire Inc.Alvotech Announces Participation at BofA Securities Healthcare Conference 2024NASDAQ:ALVOAlvontech
30/04/202409:00Business WireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
30/04/202409:00GlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
24/04/202409:00GlobeNewswire Inc.Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)NASDAQ:ALVOAlvontech
19/04/202411:10GlobeNewswire Inc.Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
16/04/202422:43Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
16/04/202422:30GlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
03/04/202412:41GlobeNewswire Inc.Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024NASDAQ:ALVOAlvontech
22/03/202420:15GlobeNewswire Inc.Alvotech Announces Increase in Number of Own SharesNASDAQ:ALVOAlvontech
20/03/202420:15GlobeNewswire Inc.Alvotech Reports Financial Results for Full Year 2023 and Provides a Business UpdateNASDAQ:ALVOAlvontech
20/03/202411:17IH Market NewsU.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices DipNASDAQ:ALVOAlvontech
05/03/202421:00GlobeNewswire Inc.Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ETNASDAQ:ALVOAlvontech
29/02/202421:05GlobeNewswire Inc.Alvotech Appoints Interim Chief Quality OfficerNASDAQ:ALVOAlvontech
26/02/202409:25GlobeNewswire Inc.Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per ShareNASDAQ:ALVOAlvontech
24/02/202401:15GlobeNewswire Inc.Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NASDAQ:ALVOAlvontech
24/02/202401:15Business WireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NASDAQ:ALVOAlvontech
15/02/202411:30GlobeNewswire Inc.Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
29/01/202409:00GlobeNewswire Inc.Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®NASDAQ:ALVOAlvontech
19/01/202417:31Dow Jones NewsAlvotech Shares Climb After FDA Concludes Facility InspectionNASDAQ:ALVOAlvontech
19/01/202416:30GlobeNewswire Inc.Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04NASDAQ:ALVOAlvontech
10/01/202408:30GlobeNewswire Inc.STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to StelaraNASDAQ:ALVOAlvontech
03/01/202408:30GlobeNewswire Inc.Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)NASDAQ:ALVOAlvontech
29/11/202309:00GlobeNewswire Inc.Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®NASDAQ:ALVOAlvontech
28/11/202321:15GlobeNewswire Inc.Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business UpdateNASDAQ:ALVOAlvontech
21/11/202313:00GlobeNewswire Inc.Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ETNASDAQ:ALVOAlvontech
14/11/202312:00GlobeNewswire Inc.Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
10/11/202314:30GlobeNewswire Inc.STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to StelaraNASDAQ:ALVOAlvontech
07/11/202313:00GlobeNewswire Inc.Alvotech to Present at the Jefferies 2023 London Healthcare ConferenceNASDAQ:ALVOAlvontech
12/10/202309:00GlobeNewswire Inc.Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04NASDAQ:ALVOAlvontech
 Showing the most relevant articles for your search:NASDAQ:ALVO

Your Recent History

NYSE
RKT
Rocket Companies
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved